Riskpilot← Back to searchSign inGet full accessHEMODX AS
ASActiveOrg 925006939Skogfaret 25B, 0382 OsloDiagnostic imaging services and medical laboratory activities · NACE 8691Est. 20203 employees
Revenue 2024
NOK 440K
-82% vs 2023
EBITDA margin
-339.6%
0% vs 2023
Equity ratio
-136.5%
Financial strength
Net profit 2024
NOK -1,5M
+1% vs 2023
| Revenue | NOK 440K | -82% |
| EBITDA | NOK -1,5M | +0% |
| Net profit | NOK -1,5M | +1% |
| Total assets | NOK 1M | -58% |
| Equity | NOK -1,4M | -3021% |
| Employees | 3 | — |
Legal name
HEMODX AS
Org number
925006939
Legal form
Aksjeselskap
NACE code
8691 · Diagnostic imaging services and medical laboratory activities
Founded
29. april 2020
Share capital
NOK 35 282
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Styrets leder eller nestleder hver for seg.
Company purpose
Internasjonal rådgivning, diagnostikk- og laboratorievirksomhet, annen utviklings- og konsulentvirksomhet, handelsvirksomhet, kjøp og salg av aksjer samt deltakelse i annen næringsvirksomhet.
Address
Skogfaret 25B, 0382 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 550 | 278 | 1 180 | 2 450 | 440 |
| Staff expenses | −403 | −597 | −451 | −1 787 | −1 793 |
| EBITDA | 5 | −627 | 436 | −1 496 | −1 494 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 5 | −627 | 436 | −1 496 | −1 494 |
| Net financials | 0 | −25 | −26 | 4 | 18 |
| Profit before tax | 5 | −652 | 410 | −1 492 | −1 476 |
| Tax | 1 | −0 | −0 | −0 | −0 |
| Net profit | 4 | −652 | 410 | −1 492 | −1 476 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 414 | 447 | 1 507 | 2 488 | 1 045 |
| Equity | 34 | −123 | 787 | 49 | −1 427 |
| Long-term debt | 0 | 0 | 0 | 1 785 | 1 985 |
| Short-term debt | 380 | 570 | 720 | 654 | 487 |
| Total debt | 380 | 570 | 720 | 2 439 | 2 472 |
EBITDA margin
-339.6%
This company
15.8%
Market median
-2249% vs market
20202024
Equity ratio
-136.5%
This company
38.2%
Market median
-457% vs market
20202024
Return on equity
-147578800.0%
This company
18.4%
Market median
-802058796% vs market
20202024
Net profit margin
-335.4%
This company
8.1%
Market median
-4241% vs market
20202024
Asset turnover
0.42×
This company
1.12×
Market median
-63% vs market
20202024
Debt / equity
1.73×
This company
0.62×
Market median
-179% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-04-17 – 2020-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 22.9% | 22.9% | 2022 | |
Investor Corporate As | Company | 19.2% | 19.2% | 2022 |
Hathon Holding As | Company | 8.4% | 8.4% | 2022 |
| Individual | 4.6% | 4.6% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of HEMODX AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Christin Kaiander | Board of Directors | 0 companies |
| Håkon Sæterøy | Chairman | 0 companies |
| Praveen Sharma | Board of Directors | 0 companies |